CN103159729A - α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 - Google Patents
α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 Download PDFInfo
- Publication number
- CN103159729A CN103159729A CN2012104021559A CN201210402155A CN103159729A CN 103159729 A CN103159729 A CN 103159729A CN 2012104021559 A CN2012104021559 A CN 2012104021559A CN 201210402155 A CN201210402155 A CN 201210402155A CN 103159729 A CN103159729 A CN 103159729A
- Authority
- CN
- China
- Prior art keywords
- mangostin
- gamma
- alpha
- human
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
一种α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用,所述的倒捻子素衍生物具有如下结构:
Description
技术领域
本发明涉及α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用。
背景技术
癌症目前已经成为威胁人类健康和生活素质的最大的疾病之一,利用我国丰富的自然资源,从中寻找前有效单体,并通过修饰改造获得高效、高选择性、低毒的抗癌药物是当前抗癌药物的主要研究方向。
肿瘤的化学预防是降低癌症发病率最直接的方法之一。为了战胜癌症等严重危害人体健康的疾病,人们不断地从植物中寻找新的治疗药物。近年来,倒捻子素的抗癌作用逐渐被人们得到证实。目前,针对高发癌症如肺癌、胃癌、肝癌、乳腺癌和结肠癌等进行研究,倒捻子素都体现很好的抗癌效果,并且逐步深入到倒捻子素的抗癌机制。
以天然产物中的活性成分为母体化合物,根据药物分子学的原理进行结构修饰,设计出可能具有高活性、低毒副作用的半合成化合物,从而发现可能应用于临床的新分子实体是目前新药开发的一种重要手段。
发明内容
本发明的目的是提供一种经过化学修饰的α-,γ-倒捻子素衍生物,及其在用于治疗癌症的药物的应用。
本发明的α-,γ-倒捻子素衍生物为下式所示:
式中的R1,R2,R3,R4所代表的基团为:
R1为H,CH2COOCH2CH3,CH2CH2CH2Cl,CH2C6H5,SO2C6H5;
R2为H,CH2CH2CH2CH3,CH2CHOCH2,CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,CH2C=C(CH3)2,COCH2Cl,SO2C6H5;
R3为,CH2CH2CH2CH3,CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,CH2CHOCH2,CH2C=C(CH3)2,SO2C6H5;
R4为CH3,CH2CH2CH2CH3, CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,SO2C6H5,CH2C=C(CH3)2,CH2CHOCH2,COCH2Cl,SO2Ph;
R5为CH2C=C(CH3)2,CH2CH2CH(CH3)2。
本发明所述的α-,γ-倒捻子素衍生物,是从山竹果壳中提取,经分离纯化得到的α-, γ-倒捻子素经过化学修饰得到的化合物。
制备本发明所述的α-,γ-倒捻子素衍生物的反应如以下反应式所示:
通过体外癌细胞抑制试验表明,本发明所述的α-,γ-倒捻子素衍生物对多种肿瘤细胞诸如人肺癌细胞株(A549)、人白血病细胞(K562)、人鼻咽癌细胞(CNE)、人口腔上皮癌细胞(KB-3-1)、人乳腺癌细胞株(MCF-7)和人肝癌细胞株(HepG2)有显著的抑制作用,而对正常细胞毒性较低。部分衍生物对A549、MCF-7和HepG2肿瘤细胞的抑制作用比相应的倒捻子素和ADM都强,因此发明的部分倒捻子素衍生物可用于制备治疗癌症的药物。
具体实施方式
本发明将通过以下实施例作进一步说明。
实施例1。
1-羟基-3,6-二丁氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-1)的制备:
取α-倒捻子素0.14g(0.34mmol)于氮气保护的25mL三口瓶中,加入研磨好的无水碳酸钾0.40g(约2.7mmol),加入6mL干燥的DMF,控制温度在30℃,缓慢滴加0.10ml BrCH2CH2CH2CH3(1.0mmol)与3 mL DMF的混合液,半小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,2.5小时后终止。过滤,滤液用60mL蒸馏水稀释,乙酸乙酯60mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(硅胶,200-300目;洗脱剂,石油醚/乙酸乙酯=80:1)纯化,得淡黄色固体粉末0.08g,产率45.1%,m.p.92.3~94.8℃;
1H NMR (CDCl3,ppm) δ: 0.987~1.025 (m, 6H), 1.518~1.578 (m,4H), 1.678 (s, 1H), 1.680 (s, 1H), 1.799 (s, 1H), 1.813~1.839 (m, 6H), 1.850 (s, 1H), 1.871~1.896 (m, 6H), 3.360 (d, J = 7.2Hz, 2H),4.030 (t, J = 6.6Hz, 2H), 4.076 (t, J = 6.6Hz, 2H), 4.131 (d, J = 7.2Hz, 2H), 5.244~5.258 (m, 2H), 6.285 (s, 1H), 6.707 (s, 1H), 13.505 (s, 1H);
13C NMR (CDCl3, ppm): δ:181.99, 162.87, 159.80, 157.48, 155.29, 155.15, 144.02, 137.09, 131.66, 131.32, 123.34, 122.52, 111.85, 111.45, 103.82, 98.67, 89.21, 68.53, 60.81, 31.17, 30.98, 26.18, 25.93, 25.85, 21.46, 19.33, 19.29, 18.19, 17.80, 13.84, 13.80.
ESI-MS m/z 523 ([M+H]+,20%)。
实施例2。
1-羟基-3,6-二(2,3-环氧丙基)氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-2)的制备:
取α-倒捻子素0.14g(0.34mmol)于氮气保护的25mL三口瓶中,加入研磨的无水碳酸钾0.40g(约2.7mmol),加入6mL干燥的DMF,控制温度在35℃,缓慢滴加0.10ml ClCH2CHOCH2(1.0mmol)与3 mL DMF的混合液,半小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,3.5小时后终止。过滤,滤液用60mL蒸馏水稀释,乙酸乙酯60mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(硅胶,200-300目;洗脱剂,石油醚/乙酸乙酯=8:1)纯化,得淡黄色固体粉末0.07g,产率39.2%,m.p.129~132℃;
1H NMR (CDCl3,ppm) δ: 1.686 (s, 6H), 1.817 (s, 3H), 1.853 (s, 3H), 2.796~2.808 (m, 1H), 2.834~2.846 (m, 1H), 2.943~2.983 (m, 2H), 3.390 (d, J = 7.2Hz, 2H), 3.402~3.418 (m, 1H), 3.445~3.461 (m, 1H), 3.826 (s, 3H), 4.038~4.079 (m, 2H), 4.135 (d, J = 7.2Hz, 2H), 4.291~4.315 (m, 1H), 4.388~4.411 (m, 1H), 5.235 (t, J = 7.2Hz, 1H), 5.246 (t, J = 7.2Hz, 1H), 6.306 (s, 1H), 6.765 (s, 1H), 13.481 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.01, 162.07, 160.03, 156.79, 155.10, 155.00, 144.10, 137.64, 131.91, 131.68, 123.07, 122.18, 112.55, 111.80, 104.27, 99.27, 89.46, 69.48, 69.10, 60.97, 49.91, 49.78, 44.65, 44.59, 26.20, 25.92, 25.84, 21.48, 18.20, 17.83.
ESI-MS m/z 523.231 ([M+H]+,60%)。
实施例3。
1-羟基-3,6-二乙酰氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-3)的制备:
取α-倒捻子素0.14g(0.34mmol)于氮气保护的25mL三口瓶中,加入研磨好的无水碳酸钾0.40g(约2.7mmol),加入6mL干燥重蒸的DMF,控制温度在40℃,缓慢滴加 0.12mL醋酸酐(1.0mmol)与3 mL DMF的混合液,半小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,3.5小时后终止。过滤,滤液用60mL蒸馏水稀释,乙酸乙酯60mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(硅胶,200-300目;洗脱剂,石油醚/乙酸乙酯= 12:1)纯化,得淡黄色固体粉末0.08g,产率47.3%。m.p.120~121.5℃;
1H NMR (CDCl3,ppm) δ: 1.689 (s, 6H), 1.781 (s, 3H), 1.836 (s, 3H), 2.345 (s, 3H), 2.398 (s, 3H), 3.318 (d, J = 7.2Hz, 2H), 3.799 (s, 3H), 4.134 (d, J = 7.2Hz, 2H), 5.157 (t, J = 7.2Hz, 1H), 5.194 (t, J = 7.2Hz, 1H), 6.643 (s, 1H), 7.130 (s, 1H), 13.430 (s, 1H);
13C NMR(CDCl3, ppm): δ: 182.88, 168.46, 168.00, 161.00, 154.85, 154.06, 153.68, 149.41, 146.72, 139.14, 132.36, 132.28, 122.36, 121.29, 116.84, 116.21, 110.60, 107.11, 100.34, 61.69, 26.46, 25.84, 25.73, 22.30, 20.99,20.91 18.21, 17.84.
ESI-MS m/z 493.189 ([M-H]-, 65%)。
实施例4。
1-羟基-3,6,-二(3-氯丙基)氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-4)和和1,3,6,-三(3-氯丙基)氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-5)的制备:
取α-倒捻子素0.14g(0.34mmol)于氮气保护的25mL三口瓶中,加入研磨的无水碳酸钾0.40g(约2.7mmol),加入6mL干燥的DMF,控制温度在45℃,缓慢滴加 BrCH2CH2CH2Cl 0.10mL(1.0mmol, 0.10mL)与3mL DMF的混合液,1小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,3.5小时后终止。过滤,滤液用80mL蒸馏水稀释,乙酸乙酯70 mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(层析硅胶,200-300目;洗脱剂,石油醚/二氯甲烷/乙酸乙酯=30:3:0.3-10:2:0.3)纯化。
LT-4:白色固体0.05g,产率30.5%;m.p.132~134℃;
1H NMR (CDCl3,ppm) δ: 1.683 (s, 6H), 1.790 (s, 3H), 1.851 (s, 3H), 1.029 (s, 3H), 2.284~2.324 (m, 2H), 2.339~2.379 (m, 2H), 3.356 (d, J = 7.2Hz, 2H), 3.794 (s, 3H), 3.763~3.820 (m, 4H), 4.133 (d, J = 7.2Hz, 2H), 4.207 (t, J = 6.0Hz, 2H), 4.252 (t, J =6.0Hz, 2H), 5.207 (t, J = 7.2Hz, 1H), 5.243 (t, J = 7.2Hz, 1H), 6.328 (s, 1H), 6.761 (s, 1H), 13.485 (s, 1H).
ESI-MS m/z 564.357 ([M+H]+, 50%).
LT-5:白色固体0.07g,产率34.8%;m.p.99~102℃;
1H NMR (CDCl3,ppm) δ: 1.663 (s, 3H),1.673 (s, 3H), 1.773 (s, 3H), 1.862 (s, 3H), 2.289~2.329 (m, 2H), 2.338~2.2.381 (m, 2H), 2.318~ 2.412 (m, 2H), 3.3940 (d, J = 7.2Hz, 2H), 3.772 (t, J = 6.0Hz, 2H), 3.797 (s,3H), 3.816 (t, J = 7.2Hz, 2H), 3.877 (t, J = 7.2Hz, 2H), 4.036 (t, J = 6.0Hz, 2H), 4.124 (d, J = 7.2Hz, 2H), 4.208 (t, J = 6.0Hz, 2H), 4.244 (t, J = 6.0Hz, 2H), 5.142 (t, J = 7.2Hz, 1H), 5.284 (t, J = 7.2Hz, 1H), 6.597 (s, 1H), 6.744 (s, 1H);
13C NMR(CDCl3, ppm): δ: 176.20, 161.14, 157.04, 156.48, 156.01, 154.14, 143.95, 137.43, 131.41, 131.26, 123.75, 123.00, 120.58, 114.77, 110.98, 98.56, 95.07, 71.52, 64.96, 64.78, 60.90, 42.26, 41.31, 41.27, 33.46, 32.00, 31.85, 26.02, 25.88, 25.70, 22.49, 18.22, 17.99;
ESI-MS m/z 641.201 ([M+H]+, 50%).
以LT-1的配料比及合成方法获得了LT-6~LT-9。
实施例5。
1,3,6-三-O-乙酸乙酯基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-6)的制备:
得浅黄色固体0.09g,产率40.5%;反应时间3.5h;洗脱剂,石油醚/乙酸乙酯=12:1; m.p.107.5~110℃;
1H NMR (CDCl3,ppm) δ: 1.307 (t, J = 7.2Hz, H), 1.315 (t, J = 7.2Hz, H), 1.326, 1.661 (s, 6H), 1.779 (s, 3H), 1.843 (s, 3H), 3.561 (d, J = 7.2Hz, 2H), 3.861 (s, 3H), 4.106 (d, J = 7.2Hz, 2H), 4.269~4.314 (m, 6H), 4.632 (s, 2H), 4.716 (s, 2H), 4.752 (s, 2H), 5.232 (t, J = 7.2Hz, 1H), 5.253 (t, J = 7.2Hz, 1H), 6.454 (s, 1H), 6.575 (s, 1H);
13C NMR(CDCl3, ppm): δ: 175.96, 169.38, 167.95, 167.90, 160.24, 156.56, 156.06, 155.15, 153.79, 144.18, 138.01, 131.75, 131.55, 123.46, 122.56, 121.29, 115.40, 111.13, 98.63, 95.38, 71.06, 65.61, 65.45, 61.69, 61.62, 61.03, 60.94, 26.00, 25.83, 25.78, 22.66, 18.18, 17.88,14.21, 14.16;
ESI-MS m/z 669.299 ([M+H]+, 60%)。
实施例6。
1,3,6-三苄氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-7)的制备:
得淡黄色固体0.09g,产率38.5%;反应时间3h;洗脱剂,石油醚/乙酸乙酯=8:1;m.p.106~107℃;
1H NMR (CDCl3,ppm) δ: 1.528 (s, 3H), 1.1.607 (s, 3H), 1.634 (s, 3H), 1.849 (s, 3H), 3.359 (d, J = 7.2Hz, 2H), 3.845 (s, 3H), 4.179 (d, J = 7.2Hz, 2H), 4.999 (s, 2H), 5.111 (t, J = 7.2Hz, 1H), 5.142 (s, 2H), 5.204 (s, 2H), 5.329 (t, J = 7.2Hz, 1H), 6.630 (s, 1H), 6.766 (s, 1H), 7.256~7.433 (m, 12H), 7.479 (d, J = 7.2Hz, 2H), 7.589 (d, J = 7.2Hz, 2H);
13C NMR (CDCl3, ppm): δ: 176.26, 161.16, 157.16, 156.44, 155.93, 154.07, 144.18, 13.64, 137.48, 136.09, 135.97, 131.40, 131.29, 128.86, 128.74, 128.62, 128.29, 128.29, 12824, 128.14, 127.87, 127.36, 127.25, 123.87, 122.86, 121.07, 144.97, 111.19, 99.10, 95.49, 76.70, 70.55, 70.34, 60.94, 26.03, 25.27, 25.71, 22.80, 18.24, 17.86.
ESI-MS m/z 681.412 ([M+H]+, 40%)。
实施例7。
1,3,6-三苯磺酰氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-8)的制备:
得淡黄色固体0.10g,产率35.3%;反应时间2.5h;洗脱剂,石油醚/乙酸乙酯=19:1;m.p.117~120℃;
1H NMR (CDCl3,ppm) δ: 1.519 (s, 3H), 1.541 (s, 3H), 1.631 (s, 3H), 1.748 (s, 3H), 2.945 (d, J = 7.2Hz, 2H), 3.656 (s, 3H), 3.900 (d, J = 7.2Hz, 2H), 4.804 (t, J = 7.2Hz, 2H), 5.186 (t, J =7.2Hz, 2H), 7.257 (s, 1H), 7.343 (s, 1H), 7.552 (t, J =7.8Hz, 2H), 7.568 (t, J =7.2Hz, 2H), 7.609 (t, J =7.8Hz, 2H), 7.691 (t, J =7.8Hz, 1H), 7.717 (t, J =7.8Hz, 1H), 7.758 (t, J =7.8Hz, 1H), 7.908~7.950 (m, 3H), 8.007 (d, J =7.8Hz, 2H).
13C NMR (CDCl3, ppm): δ: 175.77, 154.10, 152.50, 151.81, 147.45, 146.85, 145.28, 139.68, 136.39, 135.80, 135.55, 134.91, 134.59, 134.30, 133.08, 131.73, 129.62, 129.27, 129.17, 128.70, 128.46, 128.35, 127.08, 122.85, 120.30, 120.22, 116.76, 110.34, 109.70, 61.59, 26.15, 25.68, 25.53, 23.81, 18.16, 17.87.
ESI-MS m/z 831 ([M+H]+, 20%)。
实施例8。
1,3-二羟基-6-苯甲酰氧基-7-甲氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-9)的制备:
得淡黄色固体0.08g,产率46.2%;反应时间4.5h;洗脱剂,石油醚/乙酸乙酯=8:1; m.p.191~191.8℃;
1H NMR (CDCl3,ppm) δ: 1.587 (s, 3H), 1.599 (s, 3H), 1.706 (s, 3H), 1.843 (s, 3H), 3.375 (d, J = 7.2Hz, 2H), 3.819 (s, 3H), 4.096 (d, J = 7.2Hz, 2H), 5.183 (t, J = 7.2Hz, 1H), 5.253 (t, J = 7.2Hz, 1H),.6.374 (s, 1H), 6.736 (s, 1H), 6.849 (s, 1H), 539 (t, J = 7.2Hz, 2H), 7.671 (t, J = 7.2Hz, 1H), 8.217 (d, J = 7.2Hz, 2H), 13.671(s, 1H);
13C NMR (CDCl3, ppm): δ: 182.49, 164.63, 161.02, 155.87, 155.16, 154.70, 153.68, 142.86, 137.22, 133.96, 132.24, 132.18, 130.33, 128.95, 128.28, 122.96, 121.53, 116.19, 112.09, 106.96, 101.69, 100.32, 61.93, 26.60, 25.83, 25.67, 22.36, 18.24, 17.79;
ESI-MS m/z 513 ([M-H]-, 100%)。
实施例9。
1-羟基-3,6,7-三丁氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-10)的制备:
取γ-倒捻子素0.1g(0.25mmol)于氮气保护的25mL三口瓶中,加入研磨好的无水碳酸钾0.1g(约0.72mmol),加入5mL干燥的DMF,控制温度在35℃,缓慢滴加溴代正丁烷0.12 mL(1.0mmol)和3mL DMF的混合液,半小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,2.5小时后终止。过滤,滤液用70mL蒸馏水稀释,乙酸乙酯60mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(层析硅胶,200-300目;洗脱剂,石油醚/乙酸乙酯=100:1)纯化,得淡黄色固体粉末0.07g, 产率53.8%; m.p.128~131.5℃;
1H NMR (CDCl3,ppm) δ: 0.978~1.020 (m, 9H), 1.501~1.582 (m, 6H), 1.675 (s, 6H), 1.797 (s, 3H), 1.835 (s, 3H), 1.789~ 1.880 (m, 6H), 3.555 (d, J = 7.2Hz, 2H), 3.872 (t, J = 6.6Hz, 2H), 4.026 (t, J = 6.6Hz, 2H), 4.048 (t, J = 6.6Hz, 2H), 4.130 (d, J = 7.2Hz, 2H), 5.228 (t, J = 7.2Hz, 1H), 5.242 (t, J = 7.2Hz, 1H), 6.275 (s, 1H), 6.686 (s, 1H), 13.515 (s, 1H);
13C NMR (CDCl3, ppm): δ: 181.96, 162.83, 159.79, 157.58, 155.23, 155.13, 143.26, 137.08, 131.41, 131.24, 123.73, 122.59, 111.86, 11.39, 103.82, 98.56, 89.18, 73.39, 68.44, 68.15, 32.44, 31.19, 31.04, 26.26, 25.91, 25.84, 21.47, 19.32, 19.29, 18.29, 17.79, 14.01, 13.85, 13.78;
ESI-MS m/z 565 ([M+H]+, 100%)。
实施例10。
1-羟基-3,6,7-三(3-氯丙基)氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-11)的制备:
取γ-倒捻子素0.1g(0.25mmol)于氮气保护的25mL三口瓶中,加入研磨好的无水碳酸钾0.1g(约0.72mmol),加入5mL干燥重蒸的DMF,控制温度在30℃,缓慢滴加BrCH2CH2CH2Cl 0.1mL(1.0mmol)和3mL DMF的混合液,半小时滴加完毕,再继续搅拌,薄层色谱跟踪反应进程,3.5小时后终止。过滤,滤液用70mL蒸馏水稀释,乙酸乙酯60mL*3萃取,合并萃取液,干燥过夜后蒸干滤液,硅胶柱层析(层析硅胶,200-300目;洗脱剂,石油醚/二氯甲烷/乙酸乙酯=20:5:1)纯化,得淡黄色固体粉末0.05g,产率32.4%。m.p.154~157℃;
1H NMR (CDCl3,ppm) δ: 1.682 (s, 6H), 1.791 (s, 3H), 1.830 (s, 3H), 2.236~2.276 (m, 2H), 2.288~2.328 (m, 2H), 2.354~ 2.394 (m, 2H), 4.15 (t, J = 6.0Hz, 2H), 4.125 (d, J = 7.2Hz, 2H), 4.211 (t, J = 6.0Hz, 2H), 4.255 (t, J = 6.0Hz, 2H), 5.192~5.214 (m, 2H), 6.338 (s, 1H), 6.778 (s, 1H), 13.515 (s, 1H).
13C NMR (CDCl3, ppm): δ: 181.93, 162.39, 159.90, 157.01, 155.37, 155.11, 142.65, 137.57, 131.83, 131.54, 123.33, 122.40, 112.25, 111.56, 104.09, 98.91, 89.32, 69.76, 65.13, 64.73, 41.68, 41.31, 33.41, 32.07, 31.79, 29.72, 26.23, 25.88, 25.80, 21.45, 18.32, 17.83.
ESI-MS m/z 624.6 ([M+H]+, 100%).
按照实例9、实例10的配料比及方法,可制备LT-12~18。
实施例11。
1,6-二羟基-3,7-二(2,3-环氧丙基)氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-12)的制备:
得米黄色固体0.05g,产率34.8%;反应时间4.5h;洗脱剂,石油醚/乙酸乙酯=6:1; m.p.165~167℃;
1H NMR (CDCl3, ppm) δ: 1.687 (s, 3H), 1.696 (s, 3H), 1.816 (s, 3H), 1.846 (s, 3H), 2.789~2.802 (m, 1H), 2.2.943 (d, J = 4.8Hz, 1H), 3.378 (d, J = 7.2Hz, 2H), 3.398~3.414 (m, 1H), 3.861~3.934 (m, 2H), 4.016~4.067 (m, 2H), 4.202~4.233 (m, 2H), 4.281~4.315 (m, 2H), 4.408 (d, J = 7.8Hz, 1H), 5.247 (t, J = 7.2Hz, 1H), 5.265 (t, J = 7.2Hz, 1H), 6.518 (s, 1H), 6.862 (s, 1H), 13.527 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.43, 162.27, 160.22, 155.26, 152.85, 148.55, 137.78, 132.07, 132.04, 131.56, 122.80, 122.37, 112.94, 111.72, 104.31, 102.74, 89.61, 73.08, 69.21, 65.58, 61.61, 49.91, 44.61, 25.85, 25.80, 25.43, 21.54, 18.13, 17.82;
ESI-MS m/z 509.215 ([M+H]+, 50%)。
实施例12。
1-羟基-3,6,7-三氧代乙酰乙酯基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-13)的制备:
得白色固体0.06g,产率37.3%;反应时间3.5h;洗脱剂,石油醚/乙酸乙酯=4:1; m.p.153~155℃;
1H NMR (CDCl3,ppm) δ: 1.295~1.339 (m, 9H),1.673 (s, 3H), 1.682 (s, 3H), 1.808 (s, 3H), 1.820 (s, 3H), 3.426 (d, J = 7.2Hz, 2H), 4.235 (d, J = 7.2Hz, 2H), 4.264~4.316 (m, 6H), 4.630 (s, 2H), 4.706 (s, 2H), 4.747 (s, 2H), 5.199 (t, J = 7.2Hz, 2H), 5.285 (t, J = 7.2Hz, 2H), 6.175 (s, 1H), 6.605 (s, 1H), 13.400 (s, 1H);
13C NMR (CDCl3, ppm): δ: 181.96, 169.05, 168.10, 167.54, 161.56, 160.32, 155.42, 155.16, 154.84, 142.19, 138.32, 132.27, 131.80, 122.89, 122.09, ,113.02 112.39, 104.58, 99.05, 89.27, 69.89, 65.64, 65.46, 61.83, 61.57, 61.09, 26.30, 25.89, 25.83, 21.52, 18.16, 17.83, 14.24, 14.17, 14.15;
ESI-MS m/z 653 ([M-H]-, 20%)。
实施例13。
1-羟基-3,6,7-三苄氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-14)的制备:
得浅黄色固体0.09g,产率52.4%;反应时间3.5h;洗脱剂,石油醚/乙酸乙酯=35:1; m.p.154~155℃;
1H NMR (CDCl3,ppm) δ: 1.666 (s, 3H), 1.673 (s, 3H), 1.711 (s, 3H), 1.729 (s, 3H), 3.414 (d, J = 7.2Hz, 2H), 4.150 (d, J = 7.2Hz, 2H), 4.924 (s, 2H), 5.163 (s, 2H), 5.189 (s, 2H), 5.226 (t, J = 7.2Hz, 1H), 5.264 (t, J = 7.2Hz, 1H), 6.361 (s, 1H), 6.817 (s, 1H), 7.292~7.309 (m,3H), 7.343~7.412 (m, 8H), 7.431~7.461 (m, H), 13.526 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.00, 162.41, 160.01, 157.08, 155.35, 155.09, 143.08, 137.95, 137.33, 136.32, 135.56, 131.80, 131.61, 128.47, 128.63, 128.46, 128.40, 128.33, 128.09, 128.02, 127.66, 127.22, 123.42, 122.38, 112.41, 111.91, 104.20, 99.43, 89.84, 75.40, 70.92, 70.28, 26.43, 25.89, 25.83, 21.58, 18.33, 17.80;
ESI-MS m/z 667.304 ([M+H]+, 20%)。
实施例14。
1-羟基-3,6,7-乙酰氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-15)的制备:
得浅黄色固体0.05g,产率37.4%;反应时间4h;洗脱剂,石油醚/乙酸乙酯=7:1; m.p. 181~182℃;
1H NMR (CDCl3,ppm) δ: 1.676 (s, 3H), 1.692 (s, 3H),1.780 (s, 3H), 1.806 (s, 3H), 2.326 (s, 3H), 2.348 (s, 3H), 2.360 (s, 3H), 3.22 (d, J = 7.2Hz, 2H), 4.050 (d, J = 7.2Hz, 2H), 5.114 (t, J = 7.2Hz, 1H), 5.157 (t, J = 7.2Hz, 1H), 6.665 (s, 1H), 7.305 (s, 1H), 13.326 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.72, 168.40, 168.21, 167.15, 160.97, 155.42, 155.01, 153.61, 147.38, 138.14, 137.43, 132.78, 132.37, 121.19, 121.16, 116.49, 116.38, 110.64, 107.11, 100.47, 26.74, 25.78, 25.73, 22.32, 21.01, 20.91, 20.29, 18.22, 17.85;
ESI-MS m/z 523 ([M+H]+, 20%)。
实施例15。
1-羟基-3,6,7-三苯甲酰氧基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-16)的制备:
得浅黄色固体0.07g,产率38.5%;反应时间4.5h;洗脱剂,石油醚/乙酸乙酯=15:1; m.p.156~157℃;
1H NMR (CDCl3,ppm) δ: 1.575 (s, 3H), 1.605 (s, 3H), 1.616 (s, 3H), 1.631 (s, 3H), 3.408 (d, J = 7.2Hz, 2H), 4.171 (s,2H), 5.202 (t, J = 7.2Hz, 1H), 5.214 (t, J = 7.2Hz, 1H), 6.828 (s, 1H), 7.257 (s, 1H), 7.293 (t, J = 7.8Hz, 1H), 7.435 (t, J = 7.8Hz, 2H), 7.502 (t, J = 7.8Hz, 1H), 7.545 (t, J = 7.8Hz, 3H), 7.590 (t, J = 7.8Hz, 1H), 7.675 (t, J = 7.8Hz, 1H), 7.962 (d, J = 7.2Hz, 2H), 8.129 (d, J = 7.2Hz, 2H), 8.226 (d, J = 7.2Hz, 2H), 13.419 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.88, 164.35, 164.21, 163.27, 161.05, 155.65, 155.47, 153.78, 147.95, 138.45, 137.97, 134.05, 133.95, 133.93, 132.92, 132.45, 130.33, 130.25, 130.22, 128.92, 128.69, 128.60, 128.53, 128.29, 128.06, 121.31, 121.15, 116.80, 116.50, 110.75, 107.26, 100.69, 26.9025.78, 25.68, 22.41, 18.21, 17.83;
ESI-MS m/z 707 ([M-H]-, 20%)。
实施例16。
1,6-二羟基-3,7-二(2-氯乙酰氧基)-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-17)的制备:
得浅黄色固体0.05g,产率36.7%;反应时间4h;洗脱剂,石油醚/乙酸乙酯=12:1; m.p.164~167℃;
1H NMR (CDCl3,ppm) δ: 1.687 (s, 6H), 1.767 (s, 3H), 1.801 (s, 3H), 3.320 (d, J = 7.2Hz, 2H), 4.029 (d, J = 7.2Hz, 2H), 4.325 (s, 3H), 4.387 (s, 3H), 5.102 (t, J = 7.2Hz, 1H), 5.113 (t, J = 7.2Hz, 1H), 6.642 (s, 1H), 6.819 (s, 1H), 13.487 (s, 1H);
ESI-MS m/z 547.097([M-H]-, 100%)。
实施例17。
1,3,6,7-四氧代乙酸乙酯基-2,8-双(3-甲基-2-丁烯基)-氧杂蒽-9-酮(LT-18)的制备:
得白色固体0.06g,产率31.7%;反应时间4.5h;洗脱剂,石油醚/乙酸乙酯=6:1; m.p.112~114℃;
1H NMR (CDCl3,ppm) δ: 1.292~1.334 (m, 9H), 1.655 (s, 6H), 1.776 (s, 3H), 1.811 (s, 3H), 3.570 (d, J = 7.2Hz, 2H), 4.260 (d, J = 7.2Hz, 2H), 4.266~4.309 (m, 8H), 4.622 (s, 2H), 4.629 (s, 2H), 4.713 (s, 2H), 4.729 (s, 2H), 5.224 (t, J = 7.2Hz, 2H), 6.454 (s, 1H), 6.579 (s, 1H);
13C NMR (CDCl3, ppm): δ: 175.89, 169.34, 169.15, 167.92, 167.72, 160.34, 156.58, 156.03, 154.50, 154.06, 142.15, 138.27, 131.78, 131.74, 123.40, 122.54, 121.43, 115.41, 111.15, 98.68, 95.40, 71.07, 69.87, 65.65, 65.45, 61.75, 61.63, 61.04, 60.94, 26.08, 25.81, 25.77, 22.67, 18.15, 17.88, 14.24, 14.21, 14.16,14.15;
ESI-MS m/z 741 ([M+H]+, 100%)。
实施例18。
1,3,6-三羟基-7-甲氧基-2,8-双(3-甲基-2-丁烷基)-氧杂蒽-9-酮(LT-19)的制备:
称取α-倒捻子素0.1g(0.25mmol)于氮气保护的25mL三颈瓶中,加入10ml无水甲醇,缓慢搅拌中加入10%活化处理的钯碳0.01g,加快搅拌速度,控制温度在30℃左右15分钟后通入氢气,薄层色谱跟踪,24小时后终止。过滤,乙酸乙酯多次洗涤钯炭,浓缩滤液,硅胶柱层析(层析硅胶,200-300目;洗脱剂,石油醚/二氯甲烷/乙酸乙酯=15:3:1)纯化,得淡黄色固体粉末0.04g,产率39.3%; m.p.109~114℃;
1H NMR (CDCl3, ppm) δ: 0.971 (s, 6H), 0.982 (s, 3H), 0.998 (s, 3H), 1.009 (s, 3H), 1.426~1.459 (m, 2H), 1.449~1.496 (m, 2H), 1.611~1.677 (m, 1H), 1.723~1.789 (m, 1H), 2.640~2.667 (m, 2H), 3.315~3.342 (m, 2H), 3.839 (s, 3H), 6.255 (s, 1H), 6.280 (s, 1H), 7.260 (s, 1H), 13.868 (s, 1H);
13C NMR (CDCl3, ppm): δ: 182.01, 161.11, 160.02, 155.83, 154.60, 154.38, 142.41, 139.31, 112.27, 110.94, 103.76, 101.26, 92.59, 62.27, 40.24, 37.97, 28.86, 28.27, 26.93, 25.54, 22.58, 22.50, 20.16;
ESI-MS m/z 449 ([M+Cl]-, 20%)。
实施例19。
1,3,6,7-四羟基-2,8-双(3-甲基-2-丁基)-氧杂蒽-9-酮(LT-20)的制备:
取γ-倒捻子素0.1g(0.25mmol)于氮气保护的25mL三颈瓶中,加入10ml无水甲醇,缓慢搅拌中加入10%活化处理的钯碳0.01g,加快搅拌速度,控制温度在30℃左右15分钟后通入氢气,薄层色谱跟踪,24小时后终止。过滤,乙酸乙酯多次洗涤钯炭,浓缩滤液,硅胶柱层析(层析硅胶,200-300目;洗脱剂,石油醚/二氯甲烷/乙酸乙酯=20:4:1)纯化,得淡黄色固体粉末0.04g,产率41.6%, m.p.161~163℃;
1H NMR (CDCl3,ppm) δ: 0.971 (s, 3H), 0.982 (s, 3H), 1.018 (s, 3H), 1.029 (s, 3H), 1.419~1.457 (m, 2H), 1.468~1.507 (m, 2H), 1.609 (m, 1H), (m, 2H), 1.737~1.803 (m, 2H), 2.642~2.669 (m, 2H), 3.340~3.368 (m, 2H), 6.253 (s, 1H), 6.776 (s, 1H), 13.866 (s, 1H);
13C NMR (CDCl3, ppm): δ: 181.56, 162.03, 159.95, 153.97, 152.15, 151.84, 140.60, 129.70, 110.29, 110.02, 101.82, 99.86, 91.81, 38.83, 37.55, 28.15, 27.52, 24.19, 22.46, 19.64;
ESI-MS m/z 399 ([M-H]-, 100%)。
实施例20。
倒捻子素及其衍生物对肿瘤细胞株生长的抑制作用。
选择本发明的衍生物以及天然α-,β-倒捻子素对人肺癌细胞株(A549)、人白血病细胞(K562)、人鼻咽癌细胞(CNE)、人口腔上皮癌细胞(KB-3-1)、人乳腺癌细胞株(MCF-7)和人肝癌细胞株(HepG2)的细胞毒作用。采用MTT法,作用时间:72h,测定其吸光度,分别计算抑制细胞生长达50%时化合物浓度,以IC50表示。实验结果见表1。
表1 化合物A549,K562,CNE, KB-3-1,MCF-7,HepG2细胞株的IC50值
*α-MAG是α-倒捻子素,γ-MAG是γ-倒捻子素,ADM是阳性对照物(阿霉素)。
Claims (4)
1.一种α-,γ-倒捻子素衍生物,其特征是具有如下式所示结构:
式中的R1,R2,R3,R4所代表的基团为:
R1为H,CH2COOCH2CH3,CH2CH2CH2Cl,CH2C6H5,SO2C6H5;
R2为H,CH2CH2CH2CH3,CH2CHOCH2,CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,CH2CH=C(CH3)2,COCH2Cl,SO2C6H5;
R3为,CH2CH2CH2CH3,CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,CH2CHOCH2,CH2CH=C(CH3)2,SO2C6H5;
R4为CH3,CH2CH2CH2CH3, CH2COOCH2CH3,COCH3,CH2CH2CH2Cl,COC6H5,CH2C6H5,SO2C6H5,CH2CH=C(CH3)2,CH2CHOCH2,COCH2Cl,SO2Ph;
R5为CH2CH=C(CH3)2,CH2CH2CH(CH3)2。
2.权利要求1所述的α-,γ-倒捻子素衍生物作为在制备治疗癌症的药物中的应用。
3.一种用于治疗癌症的药物,其特征是含有权利要求1所述的α-,γ-倒捻子素衍生物以及药学上可接受的辅助剂。
4.根据权利要求3所述的药物,其特征是该药物作为注射剂、片剂、丸剂、胶囊、悬浮剂或者乳剂以及其他可以作为药用的及剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012104021559A CN103159729A (zh) | 2012-10-22 | 2012-10-22 | α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012104021559A CN103159729A (zh) | 2012-10-22 | 2012-10-22 | α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103159729A true CN103159729A (zh) | 2013-06-19 |
Family
ID=48583296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012104021559A Pending CN103159729A (zh) | 2012-10-22 | 2012-10-22 | α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103159729A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456824A (zh) * | 2020-03-31 | 2021-10-01 | 四川大学华西医院 | 一种抗肿瘤载药纳米复合材料 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036180A1 (ja) * | 2010-09-16 | 2012-03-22 | 株式会社エコリソース研究所 | キサントン誘導体およびその用途 |
CN102617538A (zh) * | 2012-03-08 | 2012-08-01 | 南京大学 | 对微小核糖核酸具广谱调控作用的山酮类小分子及其合成方法和应用 |
-
2012
- 2012-10-22 CN CN2012104021559A patent/CN103159729A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036180A1 (ja) * | 2010-09-16 | 2012-03-22 | 株式会社エコリソース研究所 | キサントン誘導体およびその用途 |
CN102617538A (zh) * | 2012-03-08 | 2012-08-01 | 南京大学 | 对微小核糖核酸具广谱调控作用的山酮类小分子及其合成方法和应用 |
Non-Patent Citations (3)
Title |
---|
KETTHIP SUPHAVANICH,等: "CoMFA and CoMSIA studies on a new series of xanthone derivatives against the oral human epidermoid carcinoma (KB) cancer cell line", 《MONATSH CHEM》 * |
LY DIEU HA,等: "Cytotoxic Geranylated Xanthones and O-Alkylated Derivatives of α-Mangostin", 《CHEM.PHARM.BULL.》 * |
YULIN REN,等: "Cytotoxic and NF-κB Inhibitory Constituents of the Stems of Cratoxylum cochinchinense and Their Semi-synthetic Analogues", 《J NAT PROD.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456824A (zh) * | 2020-03-31 | 2021-10-01 | 四川大学华西医院 | 一种抗肿瘤载药纳米复合材料 |
CN113456824B (zh) * | 2020-03-31 | 2023-03-31 | 四川大学华西医院 | 一种抗肿瘤载药纳米复合材料 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101362702B (zh) | 大黄素衍生物及其在制备抗癌药物中的应用 | |
CN105732381B (zh) | 牛樟芝提取物及其制备方法和应用 | |
CN102258788B (zh) | 一种靶向传递阿霉素抗癌药的组装体及其制备方法 | |
CN105037483A (zh) | 一种细梗香草皂苷a的制备方法及其用途 | |
CN102234283B (zh) | 4′-去甲基表鬼臼毒素衍生物及其合成方法和应用 | |
CN104586945A (zh) | 啤酒花总黄酮提取物、制备方法及其作为制备预防和治疗肝损伤、癌症药物的应用 | |
CN102516344B (zh) | 一种具有抗肿瘤活性的化合物及其制备方法和应用 | |
CN104159910B (zh) | 一种甾醇类衍生物及其制备方法与应用 | |
CN102093383A (zh) | 斑蝥素酸钾及其制备方法 | |
CN107011170B (zh) | 岩藻黄质衍生物及其制备方法和应用 | |
CN106279305B (zh) | 马齿苋中酰胺类生物碱化合物及其提取分离方法 | |
CN110922440B (zh) | 吲哚氮苷类化合物及提取方法及在制备防治神经系统疾病药物中的应用 | |
CN103159729A (zh) | α-,γ-倒捻子素衍生物及其在制备抗癌药物中的应用 | |
CN101914002A (zh) | 一种蓝萼甲素的提取方法 | |
CN114642670B (zh) | 雷公藤甲素衍生物在制备治疗肿瘤耐药药物中的应用、治疗与肿瘤耐药相关的药物组合物 | |
CN105367575B (zh) | 一种叶酸类化合物、其制备方法及医药用途 | |
WO2006002105A1 (en) | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities | |
WO2013170694A1 (zh) | 木香烃内酯衍生物,其药物组合物及其制备方法和用途 | |
KR101478758B1 (ko) | 할로겐화 다이디옥시글루코오스 유도체 및 그 제조방법과 그 용도 | |
CN106366088B (zh) | 小白菊内酯衍生物,其药物组合物及其制备方法和用途 | |
CN104003998B (zh) | 冬凌草甲素14-o-取代氮芥衍生物、制备方法及用途 | |
CN102875565A (zh) | 具有抗肿瘤活性的酯化鬼臼类衍生物及其制备方法和用途 | |
CN102070573A (zh) | 一种具有抗肿瘤活性的单四氢呋喃型番荔枝内酯化合物及其应用 | |
CN105343888B (zh) | 箭根酮内酯环糊精包合物及其制备方法,以及一种药物组合物 | |
CN102757460B (zh) | 一种双氢青蒿素倍半氧锗化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130619 |